2023 U.S. Life Sciences Outlook

2023 U.S. Life Sciences Outlook | CBRE

In 2023, Pandemic-fueled demand and capital infusion will give way to more normal market conditions, with better opportunities for occupiers.

2023 Global Life Sciences Outlook - Deloitte

In the coming year, the focus will remain on embracing digital technologies, navigating a changing regulatory landscapes and market volatility, and addressing ...

2023 Global Life Sciences Outlook - Deloitte

Our 2023 global life sciences outlook explores seven trends that are expected to shape the sector. In the coming year, the focus will remain on embracing ...

Outlook | CBRE

Outlook for 2023 · Previous cycles show that any slowdown in life sciences employment likely won't be as severe as that of the broader economy. · The capital ...

Life Sciences 2023 | Clarion Partners Real Estate Investment

After record years in 2020 and 2021, U.S. life sciences sector performance moderated in 2022 and into 2023. This slowdown is largely related to ...

2023 Year-End National Life Science Market Overview | Newmark

In one of the strongest years on record, the FDA approved 55 new drugs in 2023. · Venture capital funding for life science companies decreased by 30.0% in 2023, ...

Life Sciences Update | US - Cushman & Wakefield

A spotlight on European life sciences markets and trends. Recent conditions have been challenging, but the outlook has improved. With medical advances ...

2024 Life Sciences Real Estate Perspective and Cluster Analysis - JLL

Biotechnology patent innovation was 22% higher in 2023 than it was a decade prior, driving company creation, while Evaluate Pharma forecasts worldwide pharma ...

Spotlight: Life Sciences – Trends and Outlook December - Savills

It is expected that the total for 2023 will be around 10% higher over the year at just over US$400bn. This is 20% below the five-year average or 13% below the ...

Life sciences market poised for a comeback - JLL

JLL's 2023 Life Sciences Industry and Real Estate Perspective details how the life sciences ... U.S. Life Sciences, JLL. “Markets that ...

Life sciences services industry outlook: Winter 2023 - RSM US

Life sciences services companies, particularly in the clinical research space, have maintained strong growth despite the economic headwinds of 2022.

U.S. Life Sciences Real Estate: The Long-Term Outlook Remains ...

Source: CBRE, JLL, Clarion Partners Investment Research, Q3 2023. Notes: Tier 1 includes Boston/Cambridge, San Francisco, and San Diego; Tier 2 includes Raleigh ...

Outlook for 2024: 7 Key Indicators of Progress in the Life Sciences ...

The year 2023 was a challenging year for the life sciences industry, marked by a chilly biotech financing environment, uncertainty over ...

Life Sciences: Trends & Outlook – April 2024 - Savills US

The larger pharma companies are embracing bigger deals to reduce the impending impact of patents expiring. For M&A activity, the significant ...

Pharmaceutical and life sciences: US Deals 2024 midyear outlook

We expect deal activity to remain strong in the second half of 2024 despite sustained headwinds. Some of the key considerations impacting the sector include:.

Life sciences industry outlook for 2023 and beyond - Baker Tilly

Watch our on-demand life sciences industry forecast event to help prepare for what lies ahead as you consider your strategic plans for 2023 and ...

2024 life sciences industry outlook - RSM US

The Federal Reserve's indication of potential rate cuts may signal a turnaround for life sciences equity valuations, with an expected increase ...

Under the microscope: Our 2024 outlook for life sciences

Venture capital and private equity funding in Q1 2024 was up 23% compared to Q1 2023 with $12.3 billion invested into life science companies with a location in ...

Life Sciences 2024 Dealmaking Trends & Outlook | Insights

In 2023, market activity generally bounced back to pre-pandemic levels, though still not close to the biotech market exuberance seen in 2021.

2024 Healthcare and Life Sciences Investment Outlook

That means optimism among medical device companies may begin to rise, and M&A could recover from low levels in 2023. Innovations in cardiology, robotic surgery, ...